Tuesday, May 31, 2022

< + > Could This Novel Psychedelic Compound Treat Major Depressive Disorder? Clinical Trial Seeks To Find Out

Exclusive details on Cybin's IND application with the FDA, a move that could make its CYB003 compound the first psilocybin analog to be evaluated in Phase 1/2a development.

at
Labels:

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)

< + > What's behind EHR-induced clinician burnout? And how to solve it?

When evaluating electronic health record systems to minimize documentation burden, usability is always the big challenge, says one informati...